Translational Drug Development (TD2)
Shawnna Rustenbeck has an extensive work history in finance and operations. Shawnna started their career as an Accounts Payable Specialist at RWC International LTD in 2009. In 2010, they joined Grand Canyon University as a GL Accountant. Shawnna then transitioned to the role of Accounting Supervisor at both CSW Contractors, Inc. and DLC Resources, Inc. in 2013. In 2015, they became an Assistant Controller at Fortis Networks before moving to American Solar & Roofing as a Financial Controller in 2016. In 2017, Shawnna joined Translational Drug Development (TD2) as a Controller. Shawnna then progressed to Senior Director of Finance and Operations in 2020, and eventually became the Vice President of Finance and Operations in 2023. Additionally, they recently became a Member at Chief in 2023, further expanding their professional network.
Shawnna Rustenbeck has a strong educational background in accounting and forensic accounting. Shawnna began their education at Grand Canyon University, where they obtained a Bachelor of Science (B.S.) degree in Accounting from 2011 to 2013. Seeking further expertise in the field, they pursued a Master of Business Administration (MBA) with a concentration in Forensic Accounting at Southern New Hampshire University from 2015 to 2018. Additionally, they completed a Certification in Forensic Accounting at Southern New Hampshire University from 2017 to 2018.
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.